Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Comparison of clustering tools in R for medium-sized 10x Genomics single-cell RNA-sequencing data.

Freytag S, Tian L, Lönnstedt I, Ng M, Bahlo M.

Version 2. F1000Res. 2018 Aug 15 [revised 2018 Jan 1];7:1297. doi: 10.12688/f1000research.15809.2. eCollection 2018.

2.

dtangle: accurate and robust cell type deconvolution.

Hunt GJ, Freytag S, Bahlo M, Gagnon-Bartsch JA.

Bioinformatics. 2018 Nov 8. doi: 10.1093/bioinformatics/bty926. [Epub ahead of print]

PMID:
30407492
3.

Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.

Send T, Bertlich M, Horlbeck F, Schafigh D, Freytag S, Eichhorn KW, Gräff I, Bootz F, Jakob M.

Int Forum Allergy Rhinol. 2019 Jan;9(1):120-124. doi: 10.1002/alr.22210. Epub 2018 Oct 3.

PMID:
30281938
4.

De novo and inherited private variants in MAP1B in periventricular nodular heterotopia.

Heinzen EL, O'Neill AC, Zhu X, Allen AS, Bahlo M, Chelly J, Chen MH, Dobyns WB, Freytag S, Guerrini R, Leventer RJ, Poduri A, Robertson SP, Walsh CA, Zhang M; Epi4K Consortium; Epilepsy Phenome/Genome Project.

PLoS Genet. 2018 May 8;14(5):e1007281. doi: 10.1371/journal.pgen.1007281. eCollection 2018 May.

5.

Cochlear Pericytes Are Capable of Reversibly Decreasing Capillary Diameter In Vivo After Tumor Necrosis Factor Exposure.

Bertlich M, Ihler F, Weiss BG, Freytag S, Strupp M, Canis M.

Otol Neurotol. 2017 Dec;38(10):e545-e550. doi: 10.1097/MAO.0000000000001523.

PMID:
29135875
6.

De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures.

Myers CT, Stong N, Mountier EI, Helbig KL, Freytag S, Sullivan JE, Ben Zeev B, Nissenkorn A, Tzadok M, Heimer G, Shinde DN, Rezazadeh A, Regan BM, Oliver KL, Ernst ME, Lippa NC, Mulhern MS, Ren Z, Poduri A, Andrade DM, Bird LM, Bahlo M, Berkovic SF, Lowenstein DH, Scheffer IE, Sadleir LG, Goldstein DB, Mefford HC, Heinzen EL.

Am J Hum Genet. 2017 Oct 5;101(4):516-524. doi: 10.1016/j.ajhg.2017.08.013. Epub 2017 Sep 21.

7.

Role of capillary pericytes and precapillary arterioles in the vascular mechanism of betahistine in a guinea pig inner ear model.

Bertlich M, Ihler F, Weiss BG, Freytag S, Strupp M, Jakob M, Canis M.

Life Sci. 2017 Oct 15;187:17-21. doi: 10.1016/j.lfs.2017.08.015. Epub 2017 Aug 15.

PMID:
28818391
8.

The impact of a retail prescription synchronization program on medication adherence.

Girdish C, Shrank W, Freytag S, Chen D, Gebhard D, Bunton A, Choudhry N, Polinski J.

J Am Pharm Assoc (2003). 2017 Sep - Oct;57(5):579-584.e1. doi: 10.1016/j.japh.2017.05.016. Epub 2017 Jul 29.

PMID:
28764890
9.

Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow.

Bertlich M, Ihler F, Weiss BG, Freytag S, Jakob M, Strupp M, Pellkofer H, Canis M.

Otol Neurotol. 2017 Sep;38(8):1213-1216. doi: 10.1097/MAO.0000000000001510.

PMID:
28742634
10.

brain-coX: investigating and visualising gene co-expression in seven human brain transcriptomic datasets.

Freytag S, Burgess R, Oliver KL, Bahlo M.

Genome Med. 2017 Jun 8;9(1):55. doi: 10.1186/s13073-017-0444-y.

11.

EndophilinAs regulate endosomal sorting of BDNF-TrkB to mediate survival signaling in hippocampal neurons.

Burk K, Murdoch JD, Freytag S, Koenig M, Bharat V, Markworth R, Burkhardt S, Fischer A, Dean C.

Sci Rep. 2017 May 19;7(1):2149. doi: 10.1038/s41598-017-02202-4.

12.

Endophilin-A Deficiency Induces the Foxo3a-Fbxo32 Network in the Brain and Causes Dysregulation of Autophagy and the Ubiquitin-Proteasome System.

Murdoch JD, Rostosky CM, Gowrisankaran S, Arora AS, Soukup SF, Vidal R, Capece V, Freytag S, Fischer A, Verstreken P, Bonn S, Raimundo N, Milosevic I.

Cell Rep. 2016 Oct 18;17(4):1071-1086. doi: 10.1016/j.celrep.2016.09.058. Epub 2016 Oct 6.

13.

Identity by descent fine mapping of familial adult myoclonus epilepsy (FAME) to 2p11.2-2q11.2.

Henden L, Freytag S, Afawi Z, Baldassari S, Berkovic SF, Bisulli F, Canafoglia L, Casari G, Crompton DE, Depienne C, Gecz J, Guerrini R, Helbig I, Hirsch E, Keren B, Klein KM, Labauge P, LeGuern E, Licchetta L, Mei D, Nava C, Pippucci T, Rudolf G, Scheffer IE, Striano P, Tinuper P, Zara F, Corbett M, Bahlo M.

Hum Genet. 2016 Oct;135(10):1117-25. doi: 10.1007/s00439-016-1700-8. Epub 2016 Jul 1.

PMID:
27368338
14.

In silico prioritization based on coexpression can aid epileptic encephalopathy gene discovery.

Oliver KL, Lukic V, Freytag S, Scheffer IE, Berkovic SF, Bahlo M.

Neurol Genet. 2016 Jan 14;2(1):e51. doi: 10.1212/NXG.0000000000000051. eCollection 2016 Feb.

15.

Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.

Freytag SO, Zhang Y, Siddiqui F.

Mol Ther Oncolytics. 2015;2. pii: 15006. Epub 2015 Apr 29.

16.

Systematic noise degrades gene co-expression signals but can be corrected.

Freytag S, Gagnon-Bartsch J, Speed TP, Bahlo M.

BMC Bioinformatics. 2015 Sep 24;16:309. doi: 10.1186/s12859-015-0745-3.

17.

Histaminergic H3-Heteroreceptors as a Potential Mediator of Betahistine-Induced Increase in Cochlear Blood Flow.

Bertlich M, Ihler F, Freytag S, Weiss BG, Strupp M, Canis M.

Audiol Neurootol. 2015;20(5):283-93. doi: 10.1159/000368293. Epub 2015 Jun 27.

PMID:
26139562
18.

In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence.

Veenstra JJ, Gibson HM, Freytag S, Littrup PJ, Wei WZ.

Oncoimmunology. 2015 Apr 2;4(3):e989762. eCollection 2015 Mar.

19.

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

Gibson H, Munns S, Freytag S, Barton K, Veenstra J, Bettahi I, Bissonette J, Wei WZ.

Oncoimmunology. 2015 Feb 3;4(1):e984523. eCollection 2015 Jan.

20.

Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy?

Movsas A, Ibrahim R, Elshaikh MA, Lamerato L, Lu M, Sitarik A, Pradhan D, Walker EM, Stricker H, Freytag SO, Chetty IJ, Movsas B, Siddiqui F.

Am J Clin Oncol. 2016 Dec;39(6):563-567.

PMID:
24879473
21.

Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer.

Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F, Barton K, Pegg J, Zhang Y, Cheng J, Oja-Tebbe N, Bourgeois R, Gupta N, Lane Z, Rodriguez R, DeWeese T, Movsas B.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76. doi: 10.1016/j.ijrobp.2014.02.034. Epub 2014 May 5.

22.

Coverage and efficiency in current SNP chips.

Ha NT, Freytag S, Bickeboeller H.

Eur J Hum Genet. 2014 Sep;22(9):1124-30. doi: 10.1038/ejhg.2013.304. Epub 2014 Jan 22.

23.

A network-based kernel machine test for the identification of risk pathways in genome-wide association studies.

Freytag S, Manitz J, Schlather M, Kneib T, Amos CI, Risch A, Chang-Claude J, Heinrich J, Bickeböller H.

Hum Hered. 2013;76(2):64-75. doi: 10.1159/000357567. Epub 2014 Jan 14.

24.

Comparison of three summary statistics for ranking genes in genome-wide association studies.

Freytag S, Bickeböller H.

Stat Med. 2014 May 20;33(11):1828-41. doi: 10.1002/sim.6063. Epub 2013 Dec 9.

PMID:
24323702
25.

Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.

Freytag SO, Barton KN, Zhang Y.

Gene Ther. 2013 Dec;20(12):1131-9. doi: 10.1038/gt.2013.40. Epub 2013 Jul 11.

26.

Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.

Eckert S, Freytag SB, Müller A, Klebs SH.

Blood Press. 2013 Sep;22 Suppl 1:11-21. doi: 10.3109/08037051.2013.793891. Epub 2013 May 29.

PMID:
23713686
27.

Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study.

Hagendorff A, Freytag S, Müller A, Klebs S.

Adv Ther. 2013 Apr;30(4):406-19. doi: 10.1007/s12325-013-0018-3. Epub 2013 Mar 25.

PMID:
23532555
28.

Chronic obstructive pulmonary disease (COPD) patients' disease-related preferences : a study using conjoint analysis.

Pisa G, Freytag S, Schandry R.

Patient. 2013;6(2):93-101. doi: 10.1007/s40271-013-0007-2.

PMID:
23526399
29.

A novel kernel for correcting size bias in the logistic kernel machine test with an application to rheumatoid arthritis.

Freytag S, Bickeböller H, Amos CI, Kneib T, Schlather M.

Hum Hered. 2012;74(2):97-108. doi: 10.1159/000347188. Epub 2013 Mar 1.

30.

Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer.

Barton KN, Stricker H, Elshaikh MA, Pegg J, Cheng J, Zhang Y, Karvelis KC, Lu M, Movsas B, Freytag SO.

Mol Ther. 2011 Jul;19(7):1353-9. doi: 10.1038/mt.2011.89. Epub 2011 May 17.

31.

Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).

Lu M, Freytag SO, Stricker H, Kim JH, Barton K, Movsas B.

Contemp Clin Trials. 2011 May;32(3):453-60. doi: 10.1016/j.cct.2011.01.013. Epub 2011 Feb 12.

32.

A novel method of boron delivery using sodium iodide symporter for boron neutron capture therapy.

Kumar S, Freytag SO, Barton KN, Burmeister J, Joiner MC, Sedghi B, Movsas B, Binns PJ, Kim JH, Brown SL.

J Radiat Res. 2010;51(5):621-6.

33.

Cost analysis of Topical Negative Pressure (TNP) Therapy for traumatic acquired wounds.

Kolios L, Kolios G, Beyersdorff M, Dumont C, Stromps J, Freytag S, Stuermer K.

Ger Med Sci. 2010 Jun 15;8:Doc13. doi: 10.3205/000102.

34.

Does hyperthermia increase adenoviral transgene expression or dissemination in tumors?

Siddiqui F, Kolozsvary A, Barton KN, Freytag SO, Brown SL, Kim JH.

Int J Hyperthermia. 2009 Jun;25(4):273-9. doi: 10.1080/02656730902913248.

35.

Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate.

Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M, Pegg J, Zhang Y, Karvelis KC, Siddiqui F, Kim JH, Freytag SO, Movsas B.

Mol Ther. 2008 Oct;16(10):1761-9. doi: 10.1038/mt.2008.172. Epub 2008 Aug 19.

36.

Mitigation of radiation-induced skin injury by AAV2-mediated MnSOD gene therapy.

Yan S, Brown SL, Kolozsvary A, Freytag SO, Lu M, Kim JH.

J Gene Med. 2008 Sep;10(9):1012-8. doi: 10.1002/jgm.1226.

PMID:
18613255
37.

Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells.

Kumar S, Brown SL, Kolozsvary A, Freytag SO, Kim JH.

J Neurooncol. 2008 Oct;90(1):19-24. doi: 10.1007/s11060-008-9635-0. Epub 2008 Jul 2.

38.

StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.

Gollnick H, Luger T, Freytag S, Bräutigam M; STABIEL study group.

J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1319-25. doi: 10.1111/j.1468-3083.2008.02807.x. Epub 2008 Jun 6.

PMID:
18540990
39.

Reporter gene imaging using radiographic contrast from nonradioactive iodide sequestered by the sodium-iodide symporter.

Brown SL, Freytag SO, Barton KN, Flynn MJ, Peck DJ, Dragovic AF, Jin R, Yeni YN, Fyhrie DP, Les CM, Zhu G, Kolozsvary A, Pitchford WC, Nathanson SD, Fenstermacher JD, Kim JH.

Contrast Media Mol Imaging. 2007 Sep-Oct;2(5):240-7.

PMID:
18058866
40.

Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis.

Luger TA, Gollnick H, Schwennesen T, Bextermöller R, Freytag S, Bräutigam M.

J Dtsch Dermatol Ges. 2007 Oct;5(10):908-14. English, German.

PMID:
17910673
41.

A model for optimizing adenoviral delivery in human cancer gene therapy trials.

Barton KN, Freytag SO, Nurushev T, Yoo S, Lu M, Yin FF, Li S, Movsas B, Kim JH, Brown SL.

Hum Gene Ther. 2007 Jun;18(6):562-72.

PMID:
17594241
42.

Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.

Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D, Nall C, Lu M, Ajlouni M, Movsas B, Kim JH.

Mol Ther. 2007 Sep;15(9):1600-6. Epub 2007 Jun 12.

43.

Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials.

Siddiqui F, Barton KN, Stricker HJ, Steyn PF, Larue SM, Karvelis KC, Sparks RB, Kim JH, Brown SL, Freytag SO.

Hum Gene Ther. 2007 Apr;18(4):312-22.

PMID:
17408358
44.

Prostate cancer gene therapy clinical trials.

Freytag SO, Stricker H, Movsas B, Kim JH.

Mol Ther. 2007 Jun;15(6):1042-52. Epub 2007 Apr 3. Review.

45.

Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer.

Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH.

Mol Ther. 2007 May;15(5):1016-23. Epub 2007 Mar 20.

46.

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer.

Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M, Kim JH.

Mol Ther. 2007 Mar;15(3):636-42. Epub 2007 Jan 16.

47.

Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy.

Barton KN, Stricker H, Kolozsvary A, Kohl R, Heisey G, Nagaraja TN, Zhu G, Lu M, Kim JH, Freytag SO, Brown SL.

J Urol. 2006 May;175(5):1921-5.

PMID:
16600799
48.
49.

Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.

Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M, Seely J, Kim JH, Freytag SO.

Mol Ther. 2006 Feb;13(2):347-56. Epub 2005 Nov 14.

50.

Adapting the chronic care model to treat chronic illness at a free medical clinic.

Stroebel RJ, Gloor B, Freytag S, Riegert-Johnson D, Smith SA, Huschka T, Naessens J, Kottke TE.

J Health Care Poor Underserved. 2005 May;16(2):286-96.

PMID:
15937392

Supplemental Content

Loading ...
Support Center